At a glance
ClinicalIndex Comparison Record- ✓Histologic confirmation of medulloblastoma by Memorial Sloan-Kettering Cancer Center pathology
- ✓Age ≥3 years old
- ✓Post-operative residual tumor ≤1.5 cm² on head MRI
- ✓No leptomeningeal dissemination (Chang stage M-0) on head/spine MRI and lumbar CSF cytology
- ✕Age less than 3 years
- ✕Residual tumor >1.5 cm² on post-operative head MRI
- ✕Evidence of leptomeningeal dissemination on imaging or CSF cytology positive
- ✕Evidence of extra-neural metastases
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Trial Of Radioimmunotherapy, Reduced-Dose External Beam Craniospinal Radiation Therapy With IMRT Boost, And Chemotherapy For Patients With Standard-Risk Medulloblastoma
In Brief
A clinical study evaluating cisplatin, lomustine, and 4 other interventions for Brain and Central Nervous System Tumors. Completed, enrolled 6 participants across 2 sites.
Detailed Summary
RATIONALE: Radioimmunotherapy uses radiolabeled monoclonal antibodies to locate tumor cells and deliver radioactive tumor-killing substances to them without harming normal cells. Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining intrathecal radioimmunotherapy and radiation therapy with combination chemotherapy may kill any tumor cells remaining after surgery. PURPOSE: Phase II trial to study the effectiveness of combining intrathecal radioimmunotherapy and radiation therapy with combination chemotherapy in treating patients who have undergone surgery for medulloblastoma.